MICHAEL MCGUIRE
Electrician at Briarwood Ln, Irving, TX
License number
Texas 40586
Expiration Date
Jan 26, 2018
Category
Journeyman Electrician
Address
Address
1809 Briarwood Ln, Irving, TX 75061
Phone
(404) 394-3965
Personal information
See more information about MICHAEL MCGUIRE at radaris.comName
Address
Phone
508 E Howard Ln TRLR 584, Austin, TX 78753
4615 E Rice St, Lubbock, TX 79403
Professional information
See more information about MICHAEL MCGUIRE at trustoria.com
Commissioning Engineer At Vanderlande Industries
Commissioning Engineer At Vanderlande Industries
Position:
Commissioning Engineer at Vanderlande Industries
Location:
Dallas/Fort Worth Area
Industry:
Industrial Automation
Work:
Vanderlande Industries
- Greater Atlanta Area / Vancouver BC, CA since Mar 2012
-
Commissioning Engineer
Siemens Energy & Automation
Mar 2000 - Oct 2011
-
Systems Engineer
Rapistan
- Irving,Tx Mar 1996 - Apr 1999
-
Manufacturing Manager
Education:
Irving High School 1971 - 1974
High School Diploma
High School Diploma
Nucleic Acid And Polypeptide Sequences Useful As Adjuvants
Nucleic Acid And Polypeptide Sequences Useful As Adjuvants
US Patent:
6752995, Jun 22, 2004
Filed:
Apr 15, 2002
Appl. No.:
10/123058
Inventors:
Stephen A. Johnston - Dallas TX
Michael J. McGuire - Irving TX
Michael J. McGuire - Irving TX
Assignee:
Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K 4500
US Classification:
4242781, 4242321, 514 44
Abstract:
In the present invention parapox genomes were screened using a novel expression strategy to test genes for dendritic cell recruitment activity. One gene was identified, designated as B2WL, that induces dendritic cell accumulation when expressed in skin. In additional testing a second gene, PP30, was identified that exhibited adjuvant activity in the absence of stimulating dendritic cell accumulation at the site of inoculation. When co-inoculated with an antigen-encoding plasmid, both genes acted as adjuvants in stimulating an antibody response to antigens. Furthermore, nucleic acids encoding the identified B2WL peptide adjuvant enhanced the level of protection against viral infection provided by immunization with an HA-expression plasmid. Thus, novel adjuvants for genetic immunization are identified. The invention also demonstrates the application of the linear expression element (LEE) technology for screening genomes of pathogens that may contain genes that are useful when expressed and tested in a novel context.
Dipeptidyl Peptidase-I Inhibitors And Uses Thereof
Dipeptidyl Peptidase-I Inhibitors And Uses Thereof
US Patent:
5602102, Feb 11, 1997
Filed:
May 29, 1992
Appl. No.:
7/890422
Inventors:
Dwain L. Thiele - Coppell TX
Peter E. Lipsky - Dallas TX
Michael J. McGuire - Irving TX
Peter E. Lipsky - Dallas TX
Michael J. McGuire - Irving TX
Assignee:
Board of Regents, The Univ. of TX System - Austin TX
International Classification:
A61K 3805
US Classification:
514 19
Abstract:
Therapeutic agents and methods for the treatment of immunologically mediated diseases and malignancies of myeloid cell or lymphoid cell origin. These particular methods utilize the characterization of particular activation mechanisms important to the progression of these pathologies in humans. Selective inhibition of cell types responsible for precipitating these disorders in humans are provided with therapeutic agents which include peptides capable of inhibiting dipeptidyl peptidase-I activation of proenzymes present primarily in cytotoxic T-cells and myeloid cells, such as Gly--Phe--CHN. sub. 2. Antisense oligonucleotides are also characterized which are specific for human dipeptidyl peptidase-I gene which may be used in the treatment of the described disorders.